SLC16A1 and head and neck neoplasm: In the present study, head and neck tumour xenografts treated with simvastatin showed enhanced sensitivity to MCT1 inhibition with AZD3965 as compared to vehicle treated tumours, suggesting that simvastatin could be a useful predictive indicator for the success this therapy.